Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIAMOX vs AZOPT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
Treatment of elevated intraocular pressure in open-angle glaucoma,Secondary glaucoma,Preoperative reduction of intraocular pressure in acute angle-closure glaucoma,Adjunctive treatment of edema due to congestive heart failure,Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Altitude sickness (acute mountain sickness) prophylaxis and treatment
Open-angle glaucoma,Ocular hypertension
250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
10-15 hours; prolonged to up to 24+ hours in renal impairment; clinical context: requires twice-daily dosing for continuous effect.
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 m L/min).
Metabolized primarily via hydrolysis to acetazolamide (active) and then further to inactive metabolites; minimal hepatic metabolism.
Not significantly metabolized; primarily excreted unchanged in urine via renal tubular secretion.
Renal; 70-100% unchanged by tubular secretion and passive reabsorption; p H-dependent; alkaline urine increases elimination.
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
~90% bound, primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
Approximately 33% bound to plasma proteins (mainly albumin).
0.2 L/kg; distributes into total body water; concentrates in red blood cells, kidney, and eye.
Volume of distribution is approximately 0.35 L/kg, indicating distribution primarily into extracellular fluid.
Oral: ~100% (well absorbed, but food may delay absorption).
Ocular bioavailability is not quantified due to local administration; systemic bioavailability after topical ocular dosing is approximately 70% via nasolacrimal absorption.
GFR 10-50 m L/min: 250 mg every 12 hours; GFR <10 m L/min: avoid use
No dosage adjustment required for systemic absorption is minimal. However, use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential metabolite accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
No dosage adjustment required for systemic absorption is minimal. Use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Glaucoma: 8-15 mg/kg/day orally divided every 6-8 hours; Edema: 5 mg/kg IV or IM every 6 hours
Approved for children ≥2 years: one drop in the affected eye(s) twice daily. For children <2 years: safety and efficacy not established.
Start at lowest dose (250 mg orally every 12 hours); monitor renal function and electrolytes due to increased risk of metabolic acidosis and hypokalemia
No specific dose adjustment required. Monitor for ocular irritation and systemic effects, as elderly patients may be more sensitive to adverse reactions such as hypotension or fatigue.
No FDA black box warning.
None
May cause metabolic acidosis; use caution in patients with pulmonary obstruction or emphysema.,Sulfonamide derivative; may cause hypersensitivity reactions including Stevens-Johnson syndrome.,Contraindicated in severe hepatic or renal dysfunction; may precipitate hepatic encephalopathy.,Monitor serum electrolytes and blood counts during prolonged therapy.,May impair mental alertness; caution when driving or operating machinery.
Sulfonamide allergy (cross-reactivity possible),Corneal endothelial damage (risk increased with low endothelial cell count),Bacterial keratitis (with concomitant use of topical corticosteroids or ocular trauma),Contaminated dropper tip may cause ocular infections
Hypersensitivity to acetazolamide or any sulfonamide,Severe hepatic disease or cirrhosis,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Hyperchloremic acidosis,Adrenal insufficiency
Hypersensitivity to brinzolamide or any sulfonamides,Severe renal impairment (Cr Cl <30 m L/min) or hyperchloremic acidosis
Avoid high-dose vitamin C (may increase risk of kidney stones). No other significant food interactions.
No significant food interactions known. However, avoid excessive salt intake if using systemic carbonic anhydrase inhibitors; for AZOPT, ocular use minimizes systemic effects, but caution in patients with electrolyte imbalances.
Diamox (acetazolamide) is a carbonic anhydrase inhibitor. Animal studies show teratogenic effects (limb malformations) at high doses, but human data limited. First trimester exposure may be associated with increased risk of congenital anomalies, particularly of the limbs and neural tube. Risk likely low but consider alternatives in first trimester. In second and third trimesters, no clear fetal toxicity but monitor for potential electrolyte imbalances and acidosis.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in rabbits and 20 mg/kg/day in rats. However, due to potential for fetal harm (systemic carbonic anhydrase inhibition causing acidosis), use only if clearly needed. First trimester: avoid if possible; second/third trimesters: monitor for maternal acidosis.
Acetazolamide excreted into breast milk; M/P ratio approximately 0.25 for total acetazolamide, but for free drug may be higher. Milk levels low (about 10% of maternal serum). No reported adverse effects in infants; caution in neonates with renal or hepatic impairment, or those at risk for electrolyte disturbances.
It is not known if brinzolamide is excreted in human milk. In animal studies, brinzolamide was detected in milk of lactating rats. Caution is advised; consider risk vs benefit. M/P ratio: unknown.
Pregnancy-induced pharmacokinetic changes (increased renal clearance, expanded plasma volume) may require dose adjustments. No specific guidelines; monitor clinical response and serum electrolyte levels. Consider starting at lower doses (e.g., 250 mg daily) and titrate based on response and tolerability. In severe conditions (e.g., glaucoma), maintain effective dose but monitor closely for electrolyte disturbances and metabolic acidosis.
No specific dose adjustments recommended; however, due to potential for increased systemic absorption during pregnancy (increased blood volume and ocular changes), monitor intraocular pressure closely. Use the lowest effective dose. Pharmacokinetic changes: unknown; adjust based on clinical response.
DIAMOX (acetazolamide) is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and edema. It can cause metabolic acidosis; monitor electrolytes. Avoid in severe hepatic or renal impairment. Use with caution in patients with sulfonamide allergy.
AZOPT (brinzolamide ophthalmic suspension) is a carbonic anhydrase inhibitor used for lowering intraocular pressure in ocular hypertension or open-angle glaucoma. Shake well before use; may cause transient blurred vision. Use with caution in sulfonamide allergy patients. Monitor for corneal edema and electrolyte disturbances in prolonged use.
Take exactly as prescribed; do not skip doses.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Drink plenty of fluids to prevent kidney stones.,Avoid alcohol as it may increase side effects.,Report any signs of allergic reaction (rash, hives, difficulty breathing) immediately.
Shake the bottle vigorously before each use.,Remove contact lenses before instilling and wait at least 15 minutes before reinserting.,Apply pressure to the tear duct (punctal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not touch the dropper tip to any surface to avoid contamination.,May cause temporary blurred vision; avoid driving or operating machinery until vision clears.,Report any eye pain, redness, or vision changes to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIAMOX vs AZOPT, answered by our medical review team.
DIAMOX is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; decreases aqueous humor production by inhibiting carbonic anhydrase in ciliary processes, leading to reduced intraocular pressure. Also inhibits carbonic anhydrase in renal tubules, causing bicarbonate diuresis and metabolic acidosis.. AZOPT is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIAMOX and AZOPT depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIAMOX is: 250 mg orally every 6-8 hours for glaucoma; 250-375 mg orally once daily for altitude sickness; 5 mg/kg IV or IM every 6 hours for edema in congestive heart failure. The standard adult dose of AZOPT is: One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIAMOX and AZOPT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIAMOX is classified as Category C. Diamox (acetazolamide) is a carbonic anhydrase inhibitor. Animal studies show teratogenic effects (limb malformations) at high doses, but human data limited. First trimester exposu. AZOPT is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in ra. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.